Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 31,167 shares, a decline of 53.9% from the October 15th total of 67,594 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 70,312 shares, the short-interest ratio is currently 0.4 days.
Zhengye Biotechnology Stock Performance
Shares of Zhengye Biotechnology stock opened at $1.50 on Monday. Zhengye Biotechnology has a 1 year low of $0.62 and a 1 year high of $8.01. The firm’s 50-day moving average is $1.41 and its two-hundred day moving average is $1.18.
Zhengye Biotechnology (NASDAQ:ZYBT – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter. The firm had revenue of $3.75 million for the quarter.
Analyst Ratings Changes
Get Our Latest Research Report on Zhengye Biotechnology
Zhengye Biotechnology Company Profile
Zhengye Biotechnology is a China-based veterinary biotechnology company that develops, manufactures and sells vaccines and related products for animal health. Its offerings include vaccines used to help prevent infectious diseases in livestock and poultry. The company serves customers in China’s animal agriculture sector, including producers and veterinary businesses. Its operating history dates to 2004, when its principal operating business was established. Zhengye also conducts research and development and provides technical support related to its products.
Featured Stories
- Five stocks we like better than Zhengye Biotechnology
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Zhengye Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhengye Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
